Kenvue Inc. (NYSE:KVUE) Shares Bought by Focus Financial Network Inc.

Focus Financial Network Inc. raised its position in shares of Kenvue Inc. (NYSE:KVUE) by 10.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 11,529 shares of the company’s stock after acquiring an additional 1,095 shares during the quarter. Focus Financial Network Inc.’s holdings in Kenvue were worth $246,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Grove Bank & Trust raised its stake in Kenvue by 438.4% in the 4th quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock valued at $25,000 after purchasing an additional 947 shares during the last quarter. Geneos Wealth Management Inc. acquired a new stake in shares of Kenvue in the fourth quarter valued at about $29,000. Riverview Trust Co acquired a new position in Kenvue during the third quarter worth about $30,000. Fortitude Family Office LLC grew its stake in Kenvue by 106.6% during the 4th quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock valued at $32,000 after acquiring an additional 777 shares in the last quarter. Finally, Ashton Thomas Securities LLC acquired a new stake in Kenvue in the 3rd quarter valued at about $35,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on KVUE. Deutsche Bank Aktiengesellschaft lowered Kenvue from a “buy” rating to a “hold” rating and dropped their price target for the company from $25.00 to $24.00 in a research report on Thursday, December 12th. Piper Sandler raised Kenvue from a “neutral” rating to an “overweight” rating and raised their target price for the stock from $21.00 to $26.00 in a research note on Monday, January 6th. Barclays lowered their price target on shares of Kenvue from $23.00 to $21.00 and set an “equal weight” rating on the stock in a research report on Friday, January 17th. Citigroup cut their price objective on shares of Kenvue from $25.00 to $21.00 and set a “neutral” rating for the company in a research report on Wednesday, January 15th. Finally, Canaccord Genuity Group dropped their price target on shares of Kenvue from $27.00 to $24.00 and set a “buy” rating for the company in a research note on Friday, February 7th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, Kenvue has an average rating of “Hold” and a consensus price target of $23.00.

Kenvue Price Performance

KVUE stock opened at $21.94 on Friday. The business’s fifty day moving average price is $21.33 and its 200 day moving average price is $22.02. Kenvue Inc. has a 12-month low of $17.67 and a 12-month high of $24.46. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The company has a market capitalization of $42.07 billion, a PE ratio of 41.40, a P/E/G ratio of 2.16 and a beta of 1.45.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. On average, sell-side analysts anticipate that Kenvue Inc. will post 1.05 EPS for the current year.

Kenvue Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th will be given a dividend of $0.205 per share. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.74%. The ex-dividend date is Wednesday, February 12th. Kenvue’s dividend payout ratio is currently 154.72%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.